IMRT 2018

… Key Phase 3 trial demonstrating equivalence of HFRT and CFRT without use of ADT.

PROFIT

N= 1206 patients

✓ The PROFIT trial included patients with intermediate risk disease

78 Gy (39 x 2 Gy) vs 60 Gy ( 20 x 3 Gy)

✓ Showed that 60Gy was non-inferior to 78Gy with identical 21% biochemical/clinical failure at 5 years. ✓ The 11% higher biochemical control rate in CHHiP is probably due to the routine use of androgen deprivation therapy (ADT)